Talphera (NASDAQ:TLPH) Releases Earnings Results, Beats Expectations By $0.02 EPS

Talphera (NASDAQ:TLPH) posted its quarterly earnings results on Monday. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.02, FiscalAI reports.

Talphera Trading Up 3.0%

Shares of TLPH stock opened at $0.83 on Monday. Talphera has a twelve month low of $0.38 and a twelve month high of $1.57. The company’s 50-day moving average price is $0.89 and its 200-day moving average price is $1.05. The stock has a market cap of $38.82 million, a price-to-earnings ratio of -2.19 and a beta of 0.47.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Talphera in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $6.00.

Insider Activity

In other news, CFO Raffi Asadorian purchased 45,000 shares of the business’s stock in a transaction dated Thursday, February 12th. The stock was acquired at an average price of $0.81 per share, for a total transaction of $36,450.00. Following the acquisition, the chief financial officer directly owned 91,256 shares of the company’s stock, valued at approximately $73,917.36. This represents a 97.28% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Shakil Aslam purchased 35,000 shares of Talphera stock in a transaction dated Thursday, February 12th. The shares were purchased at an average cost of $0.81 per share, for a total transaction of $28,350.00. Following the transaction, the insider owned 83,178 shares in the company, valued at approximately $67,374.18. This trade represents a 72.65% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 220,364 shares of company stock valued at $178,495 over the last three months. 5.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Group One Trading LLC increased its stake in Talphera by 3,224.0% during the third quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock worth $27,000 after acquiring an additional 29,500 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Talphera in the 3rd quarter valued at $29,000. Persistent Asset Partners Ltd purchased a new position in shares of Talphera during the 4th quarter worth $42,000. Mariner LLC grew its holdings in shares of Talphera by 132.0% during the 4th quarter. Mariner LLC now owns 58,000 shares of the company’s stock worth $66,000 after purchasing an additional 33,000 shares during the period. Finally, Dauntless Investment Group LLC acquired a new stake in shares of Talphera during the 3rd quarter worth about $89,000. 37.67% of the stock is currently owned by hedge funds and other institutional investors.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.